Per Källblad

Per Källblad has a diverse work experience in the field of pharmaceuticals and bioinformatics. Per co-founded and served as the CEO of Beactica Therapeutics, a precision oncology company focused on developing small molecule therapeutics for genetically defined cancers. Prior to that, they worked as a Senior Scientist at Medivir AB. Per was also a Founding Scientist at De Novo Pharmaceuticals, where they contributed to the development of de novo structure-based drug design tools. Additionally, they worked as a Genome Curator at the European Bioinformatics Institute.

Per Källblad received their M.Sc. in Molecular Biology from the University of Gothenburg, where they studied from 1991 to 1995. In 1993 and 1994, they also pursued studies in Cell Biology and Immunology at Université Grenoble Alpes. Per went on to complete their Ph.D. in Drug Design at the University of Cambridge, from 1996 to 2000. From 2004 to 2006, Per attended Stockholm University's School of Business, although the degree obtained is unspecified.